FindTrial
Sign In

A clinical study to assess response of a drug that treats low red blood cells count in chronic kidney disease patients

A prospective observational study to assess serum magnesium level and its correlation with ESA responsiveness in anemia in CKD patients at a tertiary care hospital in Uttarakhand - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/060994
Enrollment
121
Registered
2024-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 2: N184- Chronic kidney disease, stage 4 (severe) Health Condition 3: N185- Chronic kidney disease, stage 5 Health Condition 4: N186- End stage renal disease

Interventions

Intervention1: NIL: NIL

Sponsors

BHAWNA SAINI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years of either sex 2. Patients that have CKD Stage-3-5

Exclusion criteria

Exclusion criteria: 1. Infectious disease 2. Active liver disease 3. Neoplastic disease on cytotoxic chemotherapy 4. Recent cardio-cerebrovascular disease 5. Blood transfusions or surgical procedures within last 4 weeks 6. Active bleeding or pure red cell aplasia 7. Patients receiving phosphate binder containing magnesium or laxatives containing magnesium.

Design outcomes

Primary

MeasureTime frame
•To study the serum magnesium level in CKD stage 3-5 patientsTimepoint: •To study the serum magnesium level in CKD stage 3-5 patients—

Secondary

MeasureTime frame
To correlate serum magnesium level with the erythropoiesis stimulating agents responsiveness in the anemia in chronic kidney disease patientTimepoint: BASELINE (DAY-1) AND AFTER 1 MONTH;To correlate serum magnesium level with the severity of anemiaTimepoint: BASELINE (DAY-1) AND AFTER 1 MONTH;To identify adverse drug reactions associated with erythropoiesis stimulating agents responsiveness in the anemia in chronic kidney disease patientTimepoint: BASELINE (DAY-1) AND AFTER 1 MONTH—

Countries

India

Contacts

Public ContactDr Puneet Dhamija

AIIMS, RISHIKESH

puneet.phar@aiimsrishikesh.edu.in8475000292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026